Interestingly, recent results of a phase 3 clinical trial in patients with metastatic melanoma showed that anti-LAG-3 antibody combined with anti-PD-1 improves overall survival in patients with metastatic melanoma, compared with anti-PD-1 monotherapy [27]. The gene discussed is LAG3; the disease is metastatic melanoma.